TABLE 2.
Characteristics of patients with leukemia treated with myeloablative conditioning with 3‐day total marrow and lymphoid irradiation
| Case | Dose | Age (years)/sex | PS | Disease | Disease status | MRD status | Donor source | Donor Age/sex | HLA disparity | HCT‐CI | GVHD prophylaxis |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 14 | 35/M | 0 | CML | CP2 | (+) | UBM | 34/M | 8/8 | 0 | FK + sMTX |
| 2 | 14 | 47/M | 0 | Ph+ ALL | CR1 | (+) | UBM | 47/M | 7/8 | 0 | FK + sMTX |
| 3 | 14 | 44/M | 0 | Ph+ ALL | CR1 | (+) | UBM | 26/M | 8/8 | 0 | FK + sMTX |
| 4 | 16 | 42/M | 0 | Ph+ ALL | CR2 | (−) | UBM | 40/M | 7/8 | 0 | FK + sMTX |
| 5 | 16 | 38/M | 0 | B‐ALL | CR1 | (+) | UBM | 24/M | 7/8 | 0 | FK + sMTX |
| 6 | 16 | 39/M | 0 | Ph+ ALL | CR1 | (+) | UBM | 36/M | 8/8 | 1 | FK + sMTX |
| 7 | 18 | 46/M | 1 | B‐ALL | CR1 | (+) | UBM | 31/F | 8/8 | 1 | FK + sMTX |
| 8 | 18 | 36/M | 0 | Ph+ ALL | CR1 | (−) | UBM | 24/M | 7/8 | 1 | FK + sMTX + ATG |
| 9 | 18 | 48/F | 0 | B‐ALL | CR2 | (+) | UBM | 32/F | 7/8 | 5 | FK + sMTX + ATG |
Abbreviations: ALL, acute lymphoblastic leukemia; ATG, antithymocyte globulin; B‐ALL, B‐cell acute lymphoblastic leukemia; CML, chronic myeloid leukemia; CP, chronic phase; CR, complete remission; F, female; FK, tacrolimus; GVHD, graft‐versus‐host disease; HCT‐CI, hematopoietic cell transplantation‐comorbidity index; HLA, human leukocyte antigen; M, male; MRD, measurable residual disease; Ph, Philadelphia chromosome; PS, performance status; sMTX, short‐term methotrexate; UBM, unrelated bone marrow.